Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC3022990910;90911;90912 chr2:178552215;178552214;178552213chr2:179416942;179416941;179416940
N2AB2858885987;85988;85989 chr2:178552215;178552214;178552213chr2:179416942;179416941;179416940
N2A2766183206;83207;83208 chr2:178552215;178552214;178552213chr2:179416942;179416941;179416940
N2B2116463715;63716;63717 chr2:178552215;178552214;178552213chr2:179416942;179416941;179416940
Novex-12128964090;64091;64092 chr2:178552215;178552214;178552213chr2:179416942;179416941;179416940
Novex-22135664291;64292;64293 chr2:178552215;178552214;178552213chr2:179416942;179416941;179416940
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: K
  • RefSeq wild type transcript codon: AAA
  • RefSeq wild type template codon: TTT
  • Domain: Fn3-108
  • Domain position: 6
  • Structural Position: 6
  • Q(SASA): 0.4052
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
K/E rs1311556437 -0.223 0.986 N 0.524 0.201 0.402899589544 gnomAD-2.1.1 4.04E-06 None None None None N None 0 0 None 0 0 None 0 None 0 8.93E-06 0
K/E rs1311556437 -0.223 0.986 N 0.524 0.201 0.402899589544 gnomAD-4.0.0 6.15936E-06 None None None None N None 0 0 None 0 0 None 0 0 7.19672E-06 0 1.65711E-05

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
K/A 0.1837 likely_benign 0.2071 benign -0.167 Destabilizing 0.863 D 0.453 neutral None None None None N
K/C 0.4224 ambiguous 0.4975 ambiguous -0.274 Destabilizing 0.999 D 0.603 neutral None None None None N
K/D 0.5652 likely_pathogenic 0.6201 pathogenic 0.023 Stabilizing 0.997 D 0.547 neutral None None None None N
K/E 0.1452 likely_benign 0.1612 benign 0.093 Stabilizing 0.986 D 0.524 neutral N 0.436052206 None None N
K/F 0.63 likely_pathogenic 0.6954 pathogenic 0.011 Stabilizing 0.991 D 0.601 neutral None None None None N
K/G 0.3229 likely_benign 0.361 ambiguous -0.477 Destabilizing 0.99 D 0.528 neutral None None None None N
K/H 0.2874 likely_benign 0.3256 benign -0.781 Destabilizing 0.999 D 0.551 neutral None None None None N
K/I 0.175 likely_benign 0.2039 benign 0.607 Stabilizing 0.134 N 0.426 neutral N 0.492828209 None None N
K/L 0.2244 likely_benign 0.2583 benign 0.607 Stabilizing 0.759 D 0.442 neutral None None None None N
K/M 0.1552 likely_benign 0.1697 benign 0.311 Stabilizing 0.991 D 0.523 neutral None None None None N
K/N 0.3421 ambiguous 0.3759 ambiguous -0.075 Destabilizing 0.996 D 0.527 neutral N 0.469260703 None None N
K/P 0.8213 likely_pathogenic 0.8452 pathogenic 0.38 Stabilizing 0.997 D 0.555 neutral None None None None N
K/Q 0.1076 likely_benign 0.1213 benign -0.156 Destabilizing 0.996 D 0.523 neutral N 0.419351957 None None N
K/R 0.0711 likely_benign 0.0775 benign -0.366 Destabilizing 0.986 D 0.519 neutral N 0.434070694 None None N
K/S 0.2663 likely_benign 0.3081 benign -0.607 Destabilizing 0.969 D 0.503 neutral None None None None N
K/T 0.095 likely_benign 0.1023 benign -0.354 Destabilizing 0.92 D 0.49 neutral N 0.393589508 None None N
K/V 0.1364 likely_benign 0.1655 benign 0.38 Stabilizing 0.079 N 0.397 neutral None None None None N
K/W 0.7517 likely_pathogenic 0.8021 pathogenic 0.053 Stabilizing 0.999 D 0.651 neutral None None None None N
K/Y 0.5767 likely_pathogenic 0.6322 pathogenic 0.352 Stabilizing 0.997 D 0.579 neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.